Study S001552

Crossover Study Comparing the Dulaglutide (Trulicity) Pen and the Semaglutide (Ozempic) Pen

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record Study Protocol (PDF)Statistical Analysis Plan (PDF)

Registration

Registration: NCT03724981
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: NONE
Status: COMPLETED
Enrollment: 312
Start: 2018-10-18
Primary completion: 2019-04-12
Lead sponsor: Eli Lilly and Company
Conditions: Diabetes Mellitus, Type 2
Interventions: DRUG:Dulaglutide Pen; DRUG:Semaglutide Pen
Results posted: TRUE
Individual participant data sharing: YES
Secondary identifiers: OTHER:H9X-MC-B021

Registered primary outcomes

Participant Preference Between 2 Injection Devices Based on Global Preference Item [Day 1]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0015957	Assessing patient PREFERence between the dulaglutide pen and the semaglutide pen: A crossover study (PREFER). Matza LS, Diabetes, obesity & metabolism	2020	Randomized trial	PMID 31646727 DOI	registry reference BACKGROUND:31646727